K

Kymera Therapeutics

Biotech company engineering targeted protein degraders

Senior Director - Outcomes, Value & Access

Biology & BiotechConfirmed live in the last 24 hours
Full-timeWatertown, MA, USAIn-person

About the Job

Requirements

  • Advanced degree: PharmD, PhD, MD, or MS/MPH in HEOR, Epidemiology, or a related field.
  • At least 10 years of experience in Medical Affairs, HEOR, Market Access, or related roles in the biopharmaceutical industry.
  • Demonstrated leadership in building or expanding HEOR or Medical Value/Access functions.
  • Strong therapeutic experience in immunology, with dermatology and/or respiratory experience as a plus.
  • A proven track record developing payer-focused HEOR strategy, RWE programs, value communication tools, and AMCP dossiers.
  • Experience engaging directly with national and regional payer decision-makers.
  • Strong understanding of U.S. healthcare economics, HTA landscapes, and evolving value-based frameworks.
  • Ability to work collaboratively in a fast-paced, science-driven, cross-functional environment.

Responsibilities

  • Lead development and execution of the Medical Outcomes, Value & Access strategy across the immunology portfolio.
  • Serve as a core member of the Medical Affairs Team, advising on evidence generation, clinical strategy, and payer-relevant insights.
  • Drive cross-functional alignment on value strategy across Medical Affairs, HEOR, Market Access, Clinical Development, Regulatory, Commercial, and Global teams.
  • Oversee HEOR strategy, including economic modeling, treatment-pattern studies, and comparative-effectiveness analyses.
  • Guide development and validation of economic models, including budget-impact and cost-effectiveness models, to support payer decision-making.
  • Lead creation of AMCP dossiers, value narratives, and scientific payer resources.
  • Design and oversee RWE plans, including study concept refinement, protocol development, external data partnerships, and post-marketing evidence strategy.
  • Partner with Clinical Development and Data Science teams to integrate outcomes-focused endpoints into clinical trial design.
  • Build and maintain relationships with U.S. payer organizations, HTAs, integrated delivery networks, and employer groups to communicate clinical and economic value.
  • Lead scientific exchange with medical directors, formulary decision-makers, and population-health leaders.
  • Conduct advisory boards on HEOR, RWE, and access-related topics.
  • Provide leadership for value and access-related launch preparation.
  • Collaborate with Market Access to ensure scientific accuracy and strategic alignment of access resources.
  • Lead HTA readiness for future ex-U.S. markets in partnership with global teams.
  • Support field medical teams with training on HEOR, RWE, and payer communication.
  • Build and lead a high-performing Outcomes, Value & Access team, fostering a culture of scientific excellence, collaboration, and accountability.
  • Manage budgets, timelines, and resource allocation across projects and vendors.

Desired Qualifications

  • Experience supporting early-stage to launch-stage products in specialty immunology.
  • Prior leadership of field-based payer medical teams.
  • Global or ex-U.S. HEOR/HTA exposure.
  • Experience in small or mid-size biotech environments.

About the Company

Kymera Therapeutics

Biotech company engineering targeted protein degraders

Kymera Therapeutics develops therapies that remove disease-causing proteins using targeted protein degradation. The company’s Pegasus Platform helps identify which proteins to degrade and then uses molecules that recruit the cell’s waste machinery to break down those proteins, aiming to treat cancers and immune diseases. This approach can create multiple drug candidates across different diseases. Kymera’s products are advanced through collaborations, most notably with Sanofi, which supports research, licensing, and milestone-based payments. Unlike traditional drugs that inhibit a protein’s function, Kymera’s strategy eliminates the protein itself, potentially offering new treatment options for patients. The company’s goal is to deliver new, effective medicines by degrading harmful proteins, expanding options in the biopharmaceutical market and addressing unmet medical needs.

Company size
201-500
Company stage
IPO
Headquarters
Watertown, MA
Founded
2016

Recently Posted Jobs

Explore more opportunities at Kymera Therapeutics

See more jobs